Clinical Trial Search

Primary: Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared…

Primary: Flu Antibody Titers — 10.65; 10.35; 31.09; 10.35 Titers

Primary: Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity — 25.9; 11.1; 0; 6.2 percentage of participants

Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine…

Primary: Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity — 53.3; 14.7; 1.3; 12.0 percentage of participants

Primary: Number of Seropositive Subjects for H1N1 Haemagglutination Inhibition (HI) Antibodies — 5; 6 Participants

Primary: Number of Patients Reporting Confirmed Non-small-cell Lung Cancer (NSCLC) Recurrence — 37; 24 Participants — p=0.256

Primary: Determine Feasibility as Measured by Rates of Recruitment. — 66 percentage of participants

Primary: Pharmocodynamically Optimal Dose (POD) of Rapamycin as Determined by Number of Participants With Greater Than or Equal to 60% Tumor S6 Kinase Inhibition by…

Primary: Time From Start of Sugammadex Administration to Recovery of the Neuromuscular Response to a Ratio of 0.9 for Train-Of-Four (TOF) Stimulation — 79.78; 28.00; 3.17; 1.65…

Primary: Local Tolerability - First Dose — 5; 4; 9; 0 Participants

Primary: Adverse Events — 0; 0; 0 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events — 24 Participants

Primary: Perioperative Blood Loss — 1031; 836 mL — p=<0.001